SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

After a significant dip attributed to broader AI sector concerns and potential overreactions to $ORCL news, $CRWV is seeing active debate about its oversold condition and potential for a rebound. The community is closely watching for a recovery, fueled by its strong backlog and Nvidia's involvement, while also considering factors like insider selling and convertible debt. Discussions range from potential short squeezes to long-term bullish perspectives on AI infrastructure.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending as the company tests driverless cars in Austin, leading to speculation about full autonomy and future robotaxi services. The community is actively discussing the implications of this technology and potential impact on Tesla's valuation, with some pointing to high P/E ratios. Bullish sentiment is fueled by the possibility of new highs and a 'Santa Claus rally,' while bears express concerns about overvaluation and market manipulation.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is trending as traders assess its recent price drop amid concerns about AI infrastructure spending and potential rate hikes. Community discussions range from short-term bearish sentiment and technical analysis to long-term bullish outlooks based on the company's fundamentals and contracted revenue. Investors are weighing the impact of potential AI bubble concerns against IREN's growth prospects and existing deals.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

RKLB is trending due to a mix of factors including a recently aborted launch, planned share sales by Peter Beck, and broader tech sector volatility, leading to community discussion about short-term turbulence versus long-term potential. Despite these headwinds, many investors express confidence in the company's fundamentals and future growth, particularly related to the Neutron rocket and potential government contracts. The stock's movement is also influenced by speculation around a potential SpaceX IPO and its impact on the space sector.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals ($CRML) is trending amid discussions about rare earth element (REE) needs for military applications and reactions to recent drilling results from the Tanbreez Rare Earth Project. Community members are weighing the significance of these results and pondering the potential for future growth. Some are speculating on the impact of potential government investment and partnerships, while others express skepticism about the company's progress and the overall market's valuation of REE assets.

AMC Robotics Corp. engages in developing and deploying AI-enabled robotics and smart security solutions, especially for warehouse automation, enterprise security, robotics patrol/incident-response and logistics automation. The company is headquartered in New York, NY.

AMC Robotics Corp.

AMCI is trending due to its explosive move and after-hours continuation, with community members actively discussing potential price targets and the possibility of a short squeeze. The stock, a robotics de-SPAC, is garnering attention despite sector challenges, with some drawing parallels to previous high-flying stocks and anticipating further gains. Traders are closely monitoring key resistance levels and potential breakout points.

$WORKIE is the official workers memecoin on Base.

Workie

Workie crypto is trending with increased community interest, indicated by repetitive mentions of the ticker. Speculation is building around potential catalysts for the token. The community appears to be coalescing around a bullish outlook.

Radiopharm Theranostics Ltd. operates as a pre-clinical and clinical research company. It focuses on the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical need. The company is founded by Paul A. Hopper in 2021 headquartered Carlton, Australia.

Radiopharm Theranostics Ltd - ADR

RADX is trending due to significant intraday volatility following positive Phase 2b trial data, leading to discussions about potential short squeezes and the company's financial stability. Community chatter revolves around high trading volume, potential price targets, and whether the stock is overvalued or poised for further gains based on its therapeutic pipeline. The stock's webinar presentation is also a key point of discussion, with investors looking for further catalysts.

Mask Network is the core product of Dimension, which is positioned to become the bridge that connects internet users from Web 2.0 to Web 3.0. The foundational technology of Mask Network is a peer-to-peer encrypted messaging application, with new functions continuously being created around this foundation. We at Mask Network are strong believers in the ownership economy. People should own what they produce, people should own their data, their attention and the virtual space they choose to contribute to.  Mask Network integrates decentralized social messaging, borderless payment network, and decentralized file storage and sharing to provide a safe and convenient portal for users to jump right into the continent of decentralized finance and then the new world of Web 3.0.

Mask Network

MASK is trending as community members discuss its potential as an AI stock, drawing comparisons to previous runners. Positive news and a low float are contributing to the bullish sentiment, with some anticipating a continued uptrend. Chatter revolves around potential price targets, but is mostly very speculative.

Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. It also focuses on immunology and unparalleled expertise in polymer chemistry to create one-of-a-kind, highly-selective medicines with optimal therapeutic benefit. The company was founded in 1990 and is headquartered in San Francisco, CA.

Nektar Therapeutics

Nektar Therapeutics is trending as investors anticipate topline results from its Phase 2b study of Rezpegaldesleukin for alopecia areata, expected soon. The community is highly focused on the upcoming data, with some speculating on the potential impact on the stock price based on different outcomes. Discussions also include potential settlement outcomes from their lawsuit with Eli Lilly, adding another layer of speculation to the stock's movement.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Achieve Life Sciences (NASDAQ:ACHV) Share Price Passes Above Two Hundred Day Moving Average - Here's What Happened

Achieve Life Sciences (NASDAQ:ACHV) Share Price Crosses Above 200 Day Moving Average - Time to Sell...

Stonepine Capital Management LLC Takes Position in Achieve Life Sciences, Inc. $ACHV

Stonepine Capital Management LLC acquired a new stake in shares of Achieve Life Sciences, Inc. (NASDAQ:ACHV - Free Report) in the 2nd quarter, according to the company in its most recent disclosure...

Achieve Life Sciences, Inc. (NASDAQ:ACHV) Receives Average Recommendation of "Moderate Buy" from Analysts

Shares of Achieve Life Sciences, Inc. (NASDAQ:ACHV - Get Free Report) have been assigned an average rating of "Moderate Buy" from the five brokerages that are presently covering the firm, Marketbeat...

Highbridge Capital Management LLC Acquires New Stake in Achieve Life Sciences, Inc. $ACHV

Highbridge Capital Management LLC acquired a new stake in shares of Achieve Life Sciences, Inc. (NASDAQ:ACHV - Free Report) in the second quarter, according to the company in its most recent filing...

What is Zacks Small Cap's Estimate for ACHV FY2025 Earnings?

Achieve Life Sciences, Inc. (NASDAQ:ACHV - Free Report) - Equities researchers at Zacks Small Cap cut their FY2025 earnings per share estimates for Achieve Life Sciences in a report issued on Monday...

Achieve Life Sciences, Inc. $ACHV Shares Bought by Simplify Asset Management Inc.

Simplify Asset Management Inc. boosted its stake in Achieve Life Sciences, Inc. (NASDAQ:ACHV - Free Report) by 443.7% in the second quarter, according to its most recent filing with the Securities...

Achieve Life Sciences (NASDAQ:ACHV) Posts Quarterly Earnings Results, Misses Estimates By $0.04 EPS

Achieve Life Sciences (NASDAQ:ACHV - Get Free Report) posted its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.28) earnings per share for the quarter, missing the...

Shares of Achieve Life Sciences, Inc. (ACHV) soared 32% on Friday afternoon after the company said that the U.S. Food and Drug Administration (FDA) awarded the company a Commissioner's National Priority Voucher (CNPV) for its Cytisinicline.The voucher is only available to nine programs in the program’s inaugural year. The program, announced in June, aims to reduce FDA assessment times to one to two months from the standard 10 to 12 months.Achieve Life Sciences’ Cytisinicline is indicated for nicotine e-cigarette or vaping cessation. “It's been nearly two decades since a new treatment option for smoking cessation was approved, and there are currently no treatment options for vaping cessation,” Achieve CEO Rick Stewart <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/17/3168544/0/en/Achieve-Life-Sciences-Receives-FDA-Commissioner-s-National-Priority-Voucher-for-Cytisinicline-for-Treatment-of-Nicotine-Dependence-for-E-cigarette-or-Vaping-Cessation.html">said</a>.In a mid-stage trial, participants treated with Cytisinicline were found to be 2.6 times more likely to quit using nicotine e-cigarettes or vapes compared to placebo. The FDA has agreed on a late-stage trial design that, together with the mid-stage data, would support an application for approval in vaping cessation.In September, the FDA accepted the company’s application for Cytisinicline as a treatment for smoking cessation. The agency is expected to decide on the application by June 20, 2026.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ACHV">ACHV stock</a> jumped from ‘neutral’ to ‘extremely bullish’ territory while message volume rose from ‘low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:588/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_17_at_1_41_17_PM_png_6eea8f50e0.webp" alt="ACHV's Sentiment Meter and Message Volume as of 1:41 p.m. ET on Oct. 17, 2025 | Source: Stocktwits" width="588" height="62"><figcaption>ACHV's Sentiment Meter and Message Volume as of 1:41 p.m. ET on Oct. 17, 2025 | Source: Stocktwits</figcaption></figure>Other drugs awarded the voucher under the FDA program include Merck Group’s infertility treatment Pergoveris, Sanofi’s Type 1 diabetes therapy Teplizumab, Regeneron’s gene therapy DB-OTO for congenital deafness, and more.ACHV stock is up by 15% this year and down by about 20% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/kezar-life-sciences-stock-hit-with-downgrades-price-target-cuts/ch6sK5FR38U">Kezar Life Sciences Stock Hit With Downgrades And Price Target Cuts: Retail Keeps Hopes Alive</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration a 13 year old schoolboy holds single-use Vapes for Recycling in Kingston on Thames, England. (Photo by Peter Dazeley/Getty Images)

Achieve Life Sciences Stock Soars On Receiving FDA Voucher For Expediting Review Of Investigational Drug In Vaping Cessation

The program, announced in June, aims to reduce the time taken for FDA assessments from the standard 10 to 12 months to one to two months.

Equity

The program, announced in June, aims to reduce the time taken for FDA assessments from the standard 10 to 12 months to one to two months.


Shares of Revolution Medicines, Disc Medicine, and Regeneron Pharmaceuticals rose in after-hours trading on Thursday after the U.S. Food and Drug Administration (FDA) announced the first group of drugs selected for expedited review under its new National Priority Voucher pilot program.In after-hours trading on Thursday,&nbsp;<a href="https://stocktwits.com/symbol/RVMD">Revolution Medicines</a> jumped 9%,&nbsp;<a href="https://stocktwits.com/symbol/IRON">Disc Medicine</a> surged 17%, and&nbsp;<a href="https://stocktwits.com/symbol/REGN">Regeneron Pharmaceuticals</a> edged up 0.1%.FDA Names 9 Drugs For Accelerated ReviewThe FDA said nine products have been chosen for the fast-track review process, which shortens decision timelines from the usual 10–12 months to just one or two months once a complete application is filed.The selected drugs include Merck KGaA’s fertility treatment Pergoveris, Sanofi’s Type 1 diabetes therapy teplizumab, Regeneron’s gene therapy DB-OTO for congenital deafness, and ketamine for domestic manufacturing of a general anesthetic.&nbsp;Also on the list are Revolution Medicines’ RMC-6236 for pancreatic cancer, Disc Medicine’s bitopertin for porphyria, Achieve Life Sciences’ cytisinicline for nicotine vaping addiction, Dompe’s cenegermin-bkbj for blindness, and Augmentin XR for domestic manufacturing of a common antibiotic.FDA Commissioner Highlights Expedited Review EffortFDA Commissioner Marty Makary said the initiative could shorten FDA decision times from a year to "a matter of weeks” by moving promising or high-impact therapies to the front of the review line.Makary said some of the drugs selected for vouchers, including one that uses ketamine as a general anesthetic, will be manufactured in the United States. He described Regeneron’s DB-OTO, a gene therapy for congenital deafness, as “an exciting treatment,” noting that “some of these kids got normal hearing from this amazing treatment.”He added that this is just the first round of vouchers, with additional selections expected in the coming weeks.How Stocktwits Traders Reacted To FDA’s Fast-Track ListOn Stocktwits, retail sentiment toward Revolution Medicines was ‘extremely bullish’ with ‘extremely high’ message volume, while Disc Medicine saw ‘neutral’ sentiment amid similarly ‘extremely high’ activity, and Regeneron registered ‘neutral’ sentiment with ‘normal’ engagement levels.One&nbsp; user said they expect Regeneron shares to climb steadily, projecting the stock could reach the $800-$900 range within two years.&nbsp;<stembedurl>https://stocktwits.com/Iwannagofast1/message/632653980</stembedurl>Another bullish trader suggested Revolution Medicines could be an attractive takeover candidate, potentially fetching twice its current value.<stembedurl>https://stocktwits.com/ChessGM/message/632555600</stembedurl>So far this year, Revolution Medicines shares have gained 14%, Disc Medicine is up 17%, while Regeneron has declined 20%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the FDA (United States Food and Drug Administration) logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Revolution Medicines, Disc Medicine, Regeneron Stocks Jump After-Hours As FDA Fast-Tracks 9 Drugs Under New Review Program

The FDA’s new National Priority Voucher pilot helps with faster drug reviews, cutting timelines from nearly a year to weeks.

Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of cytisinicline for smoking cessation. Its products includes cytisine, a plant-based alkaloid with a binding affinity to the nicotinic acetylcholine receptor. The company was founded in October 1991 and is headquartered in Vancouver, Canada.

ACHV
Achieve Life Sciences Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ACHV News

ACHVAchieve Life Sciences Inc.